Skip to main content

Jose Miguel Lizcano De Vega

PRESENTATION! I am Associate Professor at UAB University. Since 2021, I lead the Laboratory of Protein Kinases and Cancer at VHIR. Our group investigates new cell signaling pathways that control the proliferation and survival of cancer cells. We collaborate with biopharmaceutical companies for the preclinical development of new anticancer drugs. We are interested in the role of the new MAP kinase ERK5 in cancer proliferation, and in modulation of autophagy and of stress of endoplasmic reticulum as new strategies to improve chemotherapy and immunotherapy treatments.

Institutions of which they are part

Head of group
Protein kinases in cancer research
Vall Hebron Institut de Recerca
I graduated in Biochemistry at the Universitat Autònoma de Barcelona (UAB). After obtaining a PhD in Biochemistry and Molecular Biology (Neurochemistry) at the UAB, I made a first postdoctoral stay at the Department of Biochemistry at Trinity College Dublin (1995-96), working on Molecular Pharmacology. In 1998, I joined the MRC Protein Phosphorylation Unit (Dundee, UK), where I specialized in the study of protein kinases and cellular signaling, and in their alteration in diseases such as diabetes and cancer.

In 2004, I joined the Institute of Neurosciences UAB as a Ramón y Cajal researcher. Since 2005, I am Associate Professor at the UAB Department of Biochemistry of the Faculty of Medicine. I founded the Cell Signaling group, which studies the role of protein kinases in degenerative processes such as neurodegenerative diseases and cancer. Since 2010, my interest has focused on the study of cell signaling alterations in cancer, and on the preclinical development of new antitumor drugs. I have been vice-director of the Department of Biochemistry and director of the Biochemistry Unit of the Faculty of Medicine of the UAB.

In 2021 I joined the VHIR Institute, to lead the Laboratory of Protein Kinases and Cancer, which I combine with my teaching activity on the UAB campus. The ultimate goal of my research is to understand the biochemical basis of the tumor cell, in order to develop new molecular therapies that improve the survival and quality of life of cancer patients.

Projects

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: PID2019-107561RB-I00
Duration: 01/06/2020 - 31/05/2023

Ministerio de Ciencia

Related news

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The meeting allows establishing the basis for collaboration between experts from around the world, with the aim of promoting research on this protein and its role in cancer.

Vall d’Hebron and UAB researchers studied the antitumoral action of protein kinase ERK5 inhibitor drugs, and found out they accelerate toxic autophagy.

Related professionals

Idoia Bolinaga Ayala

Idoia Bolinaga Ayala

Predoctoral researcher
Protein kinases in cancer research
Read more
Sergio Espinosa Gil

Sergio Espinosa Gil

Predoctoral researcher
Protein kinases in cancer research
Read more
Gokhan Gorgisen

Gokhan Gorgisen

Postdoctoral researcher
Protein kinases in cancer research
Read more
Laura Fresno Bermejo

Laura Fresno Bermejo

Senior researcher
Protein kinases in cancer research
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.